无容量
易普利姆玛
舒尼替尼
医学
肾细胞癌
肿瘤科
内科学
生物标志物
免疫疗法
癌症
肾癌
生物
生物化学
作者
Robert J. Motzer,Toni K. Choueiri,David F. McDermott,Peter Schmid,Yann Vano,Saurabh Gupta,Jin Yao,Celine Han,Ron Ammar,Simon Papillon‐Cavanagh,Shruti Shally Saggi,M. Brent McHenry,Petra Ross‐Macdonald,Megan Wind‐Rotolo
标识
DOI:10.1136/jitc-2021-004316
摘要
Background The phase 3 CheckMate 214 trial demonstrated higher response rates and improved overall survival with nivolumab plus ipilimumab versus sunitinib in first-line therapy for advanced clear-cell renal cell carcinoma (RCC). An unmet need exists to identify patients with RCC who are most likely to benefit from treatment with nivolumab plus ipilimumab. Methods In exploratory analyses, pretreatment levels of programmed death ligand 1 were assessed by immunohistochemistry. Genomic and transcriptomic biomarkers (including tumor mutational burden and gene expression signatures) were also investigated. Results Biomarkers previously associated with benefit from immune checkpoint inhibitor-containing regimens in RCC were not predictive for survival in patients with RCC treated with nivolumab plus ipilimumab. Analysis of gene expression identified an association between an inflammatory response and progression-free survival with nivolumab plus ipilimumab. Conclusions The exploratory analyses reveal relationships between molecular biomarkers and provide supportive data on how the inflammation status of the tumor microenvironment may be important for identifying predictive biomarkers of response and survival with combination immunotherapy in patients with RCC. Further validation may help to provide biomarker-driven precision treatment for patients with RCC.
科研通智能强力驱动
Strongly Powered by AbleSci AI